// App-Quantinova.ai

1249 : PRN1371, an irreversible, covalent inhibitor of FGFR1, 2, 3 and 4 is highly efficacious in preclinical tumor models

Researchers

Presenter

  • Eleni Venetsanakos

Principal Investigators

  • Michael Bradshaw

  • David M. Goldstein

  • Kwan Leung

  • Dane Karr

  • Yan Xing

  • Jacob LaStant

  • Philip Nunn

  • Jin Shu

  • Abha Bommireddi

  • Steven G. Gourlay

  • Jens Oliver Funk

  • Ken A. Brameld

Medical Centers

  • Principia Biopharma, South San Francisco, CA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Fibroblast growth factor receptor

Drug/Treatment

  • PRN1371

Outcome

  • N/A

Study Design

  • Randomized

  • Pharmacodynamics

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved